E-QURE has established a Scientific Advisory Board appointing Dr. Ben-Zion Weiner and Prof. Avi Ohry
The Wound Healing Medical Device company nominated two prominent, well experienced scientists, to guide the company in its coming clinical trial and industry recognition.
Sep. 17, 2014 - NEW YORK -- E-QURE Corp has established a Scientific Advisory Board as part of its comprehensive efforts to broaden its scientific base in the field of electrical stimulation treatments for ulcers. Two prominent individuals were nominated who bring substantial in depth knowledge and experience in the drug business as well as in the rehabilitation practice. The advisory board will assist the board of directors in scientific and practical guidance.
Dr. Ben-Zion Weiner has been with Teva Pharmaceuticals since 1975. In January 2006, Dr. Weiner joined the Office of the CEO and assumed the role of Chief R&D Officer. Dr. Weiner served as Group Vice President - Global Products from April 2002 until January 2006. Previously, he served as Vice President - Research and Development from 1986 to 2002. He received a Ph.D. in chemistry from the Hebrew University, where he also earned B.Sc. and M.Sc. degrees. He conducted his post-doctorate research at Schering-Plough Corporation in the United States. He was granted the Rothschild Prize for Innovation/Export two times, in 1989 for the development of Alpha D3 for dialysis and osteoporosis patients and in 1999 for the development of Copaxone® for multiple sclerosis.
Prof. Avi Ohry, MD is an Expert in rehabilitation medicine, a Consultant to the Israeli Ministry of Health, the Israeli Ministry of Defense, the Israeli Ministry of Foreign Affairs and the Reuth Medical Center & Maccabi Sick Fund of Tel Aviv. Prof. Ohry served as Member of Biomedical Advisory Board at LifeWave Ltd. Prof. Ohry is a Director at the Israeli Spinal Cord Injury Rehabilitation Unit of Sheba Medical Center since 1985 and has been an Associate Professor of Rehabilitation Medicine at Tel Aviv University since 1998.